Trial Profile
Clinical study to investigate the effects of olmesartan and azelnidipine in patients with hypertension and arteriosclerosis obliterans
Status:
Recruiting
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 10 May 2017
Price :
$35
*
At a glance
- Drugs Azelnidipine (Primary) ; Olmesartan medoxomil (Primary)
- Indications Arteriosclerosis obliterans; Essential hypertension
- Focus Therapeutic Use
- 04 Jan 2008 New trial record.